Immunocore Holdings plc Revenue from Contract with Customer, Excluding Assessed Tax
Immunocore Holdings plc (IMCR) reported Revenue from Contract with Customer, Excluding Assessed Tax of $115.93 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06
- Immunocore Holdings plc revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $115.93M, a 18.34% increase year-over-year.
- Immunocore Holdings plc revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $106.68M, a 13.63% increase year-over-year.
- Immunocore Holdings plc revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $104.48M, a 24.30% increase year-over-year.
- Immunocore Holdings plc revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $103.69M, a 29.22% increase year-over-year.
- Immunocore Holdings plc revenue from contract with customer, excluding assessed tax for fiscal 2025 was $400.02M, a 28.95% increase from fiscal 2024.
- Immunocore Holdings plc revenue from contract with customer, excluding assessed tax for fiscal 2024 was $310.20M, a 24.37% increase from fiscal 2023.
- Immunocore Holdings plc revenue from contract with customer, excluding assessed tax for fiscal 2023 was $249.43M, a 43.05% increase from fiscal 2022.
- Immunocore Holdings plc revenue from contract with customer, excluding assessed tax for fiscal 2022 was $174.36M, a 4175.65% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $115.93M 10-Q · filed 2026-08-06 | $222.60M 10-Q · filed 2026-08-06 | $327.08M derived: sum of 3 quarters · filed 2026-08-06 | $430.77M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $106.68M 10-Q · filed 2026-05-06 | $211.16M derived: sum of 2 quarters · filed 2026-05-06 | $314.85M derived: sum of 3 quarters · filed 2026-05-06 | $412.81M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $104.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $208.17M derived: sum of 2 quarters · filed 2026-02-25 | $306.13M derived: sum of 3 quarters · filed 2026-08-06 | $400.02M 10-K · filed 2026-02-25 | |
| 2025-09-30 | $103.69M 10-Q · filed 2025-11-06 | $201.66M derived: sum of 2 quarters · filed 2026-08-06 | $295.54M 10-Q · filed 2025-11-06 | $379.59M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $97.96M 10-Q · filed 2026-08-06 | $191.84M 10-Q · filed 2026-08-06 | $275.90M derived: sum of 3 quarters · filed 2026-08-06 | $356.14M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $93.88M 10-Q · filed 2026-05-06 | $177.93M derived: sum of 2 quarters · filed 2026-05-06 | $258.18M derived: sum of 3 quarters · filed 2026-05-06 | $333.58M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | $84.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $164.30M derived: sum of 2 quarters · filed 2026-02-25 | $239.70M derived: sum of 3 quarters · filed 2026-02-25 | $310.20M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $80.25M 10-Q · filed 2025-11-06 | $155.65M derived: sum of 2 quarters · filed 2025-11-06 | $226.15M 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | $75.40M 10-Q · filed 2025-08-07 | $145.90M 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | $70.50M 10-Q · filed 2025-05-07 | ||||
| 2023-12-31 | $249.43M 10-K · filed 2026-02-25 | $238.74M 10-K · filed 2024-02-28 | |||
| 2022-12-31 | $174.36M 10-K · filed 2025-02-26 | $140.69M 10-K · filed 2024-02-28 | |||
| 2021-12-31 | $4.08M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |